Can-Fite BioPharma Ltd.
TASECan-Fite BioPharma delivered the most significant clinical readout of its recent history today — but the stock heads into the weekend carrying a month of losses and a market cap of just $6.4 million, making every data point feel outsized. The headline result, announced this morning, is that namodenoson's Phase 2a trial in advanced pancreatic cancer showed over 30% of patients…
Snapshot as of 8 May 2026
Can-Fite BioPharma delivered the most significant clinical readout of its recent history today — but the stock heads into the weekend carrying a month of losses and a market cap of just $6.4 million, making every data…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for CANF — free to start on ORTEX.
Sign up for free →Open CANF on ORTEX